Institution
Purdue Pharma
Company•Pickering, Ontario, Canada•
About: Purdue Pharma is a company organization based out in Pickering, Ontario, Canada. It is known for research contribution in the topics: Buprenorphine & Chronic pain. The organization has 622 authors who have published 691 publications receiving 31545 citations. The organization is also known as: Purdue Pharmaceuticals L.P..
Topics: Buprenorphine, Chronic pain, Oxycodone, Hydrocodone, Controlled release
Papers published on a yearly basis
Papers
More filters
•
08 Jun 2007TL;DR: In this paper, sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours.
Abstract: Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.
148 citations
••
TL;DR: In an animal model,microspheres obtained from polymer or microsphere blends attained a faster onset of testosterone suppression as compared to microspheres from higher molecular weight 50:50 hydrophilic PLGA polymer, 28.3 kDa, alone, which illustrated the feasibility of blending polymers or micro spheres of varied characteristics in achieving modified drug release.
145 citations
••
TL;DR: Research that showed that average pain ratings of approximately 5 and below permit increased function and quality of life in patients with moderate to severe low back pain and osteoarthritis provides support for the use of 0–5 on a 0–10 numeric average pain severity scale as one possible criterion for a Manageable Day.
Abstract: The objective of this study was to adapt the concept of ‘episode-free day’, a metric for measuring symptom relief in daily units, to the clinical outcome literature for persistent pain. The episode-free day metric is widely used in other medical literature, but no analogous measure exists in pain literature. Prior focus groups with this population suggested that a ‘Day of Manageable Pain Control’ was an appropriate name for the metric. In the present study, in order to derive a statistical criterion for ‘Manageable Day’, we used Serlin et al.’s (Pain 61 (1995) 277) cut-point derivation method to derive a single cut-point on a 0–10 scale of average pain that divided groups with significant persistent pain optimally on pain-related functional interference. Participants were 194 patients with moderate-severe low back pain ( n =96) or osteoarthritis ( n =98). For both patient samples, ‘5’ was the cut-point that optimally distinguished groups on pain-related interference. ‘5–8’ and ‘5–7’ were double cut-point solutions that optimally divided LBP and OA samples into three categories (e.g. lowest, medium and highest average pain), respectively. Derived cut-points were confirmed using a variety of measures of functional disability. Together with research that showed that average pain ratings of approximately 5 and below permit increased function and quality of life in patients with moderate to severe low back pain and osteoarthritis, our findings provide support for the use of 0–5 on a 0–10 numeric average pain severity scale as one possible criterion for a Manageable Day.
143 citations
•
02 May 2002TL;DR: In this paper, the authors proposed sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C 24 /C max O 2 ) ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C 24 /C max oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
139 citations
••
TL;DR: The relationships between prescriptive usage of opioids and reported morbidity at the national level, using data from the Drug Abuse Warning Network, suggest that non-medical use of opioids is predictable based on potency and extent ofprescriptive use.
134 citations
Authors
Showing all 622 results
Name | H-index | Papers | Citations |
---|---|---|---|
Gideon Koren | 129 | 1994 | 81718 |
Asbjørn Mohr Drewes | 67 | 656 | 17287 |
Hilary L. Surratt | 44 | 169 | 7586 |
Ronald M. Burch | 42 | 108 | 5897 |
John F. W. Keana | 41 | 234 | 6349 |
Sui Xiong Cai | 39 | 91 | 4492 |
Howard D. Chilcoat | 39 | 91 | 8739 |
Sidney H. Schnoll | 37 | 88 | 5336 |
Paul Coplan | 36 | 121 | 4149 |
Benjamin Oshlack | 32 | 95 | 3902 |
Nabarun Dasgupta | 30 | 100 | 3366 |
Donald J. Kyle | 29 | 150 | 2390 |
Nancy C. Lan | 29 | 50 | 3597 |
Christopher D. Breder | 28 | 50 | 6748 |
Michael F. Schneider | 27 | 53 | 4862 |